ArticleCancer research2010
Immunohistochemical expression of BRCA1 and lethal prostate cancer.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 52 citations in OpenAlex.
- Mechanisms underlying prostate cancer sensitivity to reactive oxygen species: overcoming radiotherapy resistance and recent clinical advances.Cancer biology & medicine · 2025Review
- The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy.The journal of pathology. Clinical research · 2022Article
- Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis.World journal of clinical cases · 2021Article
- Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.Carcinogenesis · 2020Article
- Review
- A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors.The Prostate · 2018Article
- Mutations in BRCA2 and taxane resistance in prostate cancer.Scientific reports · 2017Article
- Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.Prostate cancer and prostatic diseases · 2016Article
- Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.The Prostate · 2015Article
- Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers.Familial cancer · 2013Article
- Network and data integration for biomarker signature discovery via network smoothed T-statistics.PloS one · 2013Article
- Image analysis tools for evaluation of microscopic views of immunohistochemically stained specimen in medical research-a review.Journal of medical systems · 2012Review
- BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer.Molecular cancer research : MCR · 2011Article
- Regulation of E2Fs and senescence by PML nuclear bodies.Genes & development · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
Abstract
BRCA1 functions as a tumor suppressor; recent work suggests that BRCA1 may also induce cell cycle arrest to allow for DNA repair. We hypothesized that BRCA1 expression in prostate tumor tissue may be associated with prostate cancer progression through regulation of the cell cycle. We used immunohistochemistry to evaluate BRCA1 protein expression in archival tumor samples from 393 prostate cancer cases in the Physicians' Health Study. The men were followed prospectively from diagnosis to development of metastases and mortality. Fifteen percent of tumors stained positive for BRCA1. BRCA1-positive tumors had substantially increased tumor proliferation index compared with negative tumors (47.0 Ki67-positive nuclei versus 10.3, P = 0.0016) and were more likely to develop lethal cancer compared with BRCA1-negative tumors (hazard ratio, 4.6; 95% confidence interval, 2.4-8.7). These findings strengthen the hypothesis that BRCA1 plays a role in cell cycle control and show that BRCA1 is a marker of clinical prostate cancer prognosis. Cancer Res; 70(8); 3136-9. (c)2010 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.